Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/31420
Title: | Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial) | Authors: | De Luca, Giuseppe Damen, Sander A. Camaro, Cyril BENIT, Edouard Verdoia, Monica Rasoul, Saman Liew, Houng Bang Polad, Jawed Ahmad, Wan A. Zambahari, Robaayah Postma, Sonja Kedhi, Elvin Suryapranata, Harry |
Issue Date: | 2019 | Publisher: | EUROPA EDITION | Source: | EuroIntervention, 15 (11) , p. e990 -e998 | Abstract: | Aims: The optimal duration of DAPT in ACS patients treated with DES is still unclear. Therefore, the aim of the current study was to investigate a short versus a standard 12-month DAPT regimen in ACS patients undergoing new-generation DES implantation. Methods and results: REDUCE was a prospective, open-label, multicentre, investigator-initiated study that randomised 1,496 ACS patients after treatment with the COMBO stent to either three (n=751) or 12 months (n=745) of DAPT. The primary study endpoint was a composite of all-cause mortality, myocardial infarction, stent thrombosis, stroke, target vessel revascularisation and bleeding at 12 months. No difference was observed in the demographic and clinical characteristics between the two groups, except for gender (p=0.01). At one-year follow-up, non-inferiority of three-versus 12-month DAPT in the primary endpoint was met (8.2% vs 8.4%, p(non-inferiority)<0.001). The similar outcome between the two groups was confirmed at two-year follow-up (11.6% vs 12.1%, p=0.76), with no significant difference in overall mortality (3.1% vs 2.2%, p=0.27), cardiac mortality (1.8% vs 1.1%, p=0.28), stent thrombosis (1.6% vs 0.8%, p=0.16) and major bleeding (3.3% vs 4.0%, p=0.46). Conclusions: The results show that, among ACS patients treated with the COMBO stent, three months is non-inferior to 12 months of DAPT. However, given the numerically higher rates of mortality and ST in the three-month DAPT group, one-year DAPT should still be recommended in ACS until more information becomes available. A three-month DAPT strategy should be considered only if clinically mandated. | Notes: | De Luca, G (reprint author), Univ Piemonte Orientale, Via Paolo Solaroli 17, I-28100 Novara, NO, Italy. giuseppe.deluca@med.uniupo.it |
Keywords: | ACS/NSTE-ACS; drug-eluting stent; STEMI | Document URI: | http://hdl.handle.net/1942/31420 | ISSN: | 1774-024X | e-ISSN: | 1969-6213 | DOI: | 10.4244/EIJ-D-19-00539 | ISI #: | WOS:000501563600012 | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Show full item record
SCOPUSTM
Citations
17
checked on Sep 7, 2020
WEB OF SCIENCETM
Citations
121
checked on Oct 9, 2024
Page view(s)
48
checked on Jun 28, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.